Login to Your Account

ISA, Regeneron to test vaccine-PD-1 combo in HPV16-associated cancers

By Cormac Sheridan
Staff Writer

Monday, December 18, 2017

DUBLIN – ISA Pharmaceuticals BV could earn well in excess of $500 million from a strategic collaboration in immuno-oncology with Regeneron Pharmaceuticals Inc., which marries its peptide-based therapeutic cancer vaccine, ISA-101, with Regeneron’s PD-1 inhibitor, cemiplimab.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription